Abbott – Free Cash Flow, Net Income & Margins

Quarterly charts & data from official filings

Timeframe

Profitability

ProfitabilityTable view

Earnings release date
Net income (shareholders)
Free cash flow
Total
Earnings release date:16 Jul. 26
Net income (shareholders):
928,000,000 $-13.8%
Free cash flow:
2,084,000,000 $+127.5%
Total:
3,012,000,000 $+51.1%
Earnings release date:16 Apr. 26
Net income (shareholders):
1,077,000,000 $-51.2%
Free cash flow:
916,000,000 $-58.0%
Total:
1,993,000,000 $-54.6%
Earnings release date:22 Jan. 26
Net income (shareholders):
2,206,000,000 $+34.2%
Free cash flow:
2,182,000,000 $-54.2%
Total:
4,388,000,000 $-31.6%
Earnings release date:15 Oct. 25
Net income (shareholders):
1,644,000,000 $+262.1%
Free cash flow:
4,769,000,000 $+195.8%
Total:
6,413,000,000 $+210.4%
Earnings release date:17 Jul. 25
Net income (shareholders):
454,000,000 $-65.7%
Free cash flow:
1,612,000,000 $+72.8%
Total:
2,066,000,000 $-8.5%
Earnings release date:16 Apr. 25
Net income (shareholders):
1,325,000,000 $-85.6%
Free cash flow:
933,000,000 $-68.5%
Total:
2,258,000,000 $-81.5%
Earnings release date:22 Jan. 25
Net income (shareholders):
9,229,000,000 $+460.7%
Free cash flow:
2,958,000,000 $-14.9%
Total:
12,187,000,000 $+137.9%
Earnings release date:16 Oct. 24
Net income (shareholders):
1,646,000,000 $+26.4%
Free cash flow:
3,477,000,000 $+81.5%
Total:
5,123,000,000 $+59.2%
Earnings release date:18 Jul. 24
Net income (shareholders):
1,302,000,000 $+6.3%
Free cash flow:
1,916,000,000 $+205.6%
Total:
3,218,000,000 $+73.8%
Earnings release date:17 Apr. 24
Net income (shareholders):
1,225,000,000 $-43.5%
Free cash flow:
627,000,000 $-66.0%
Total:
1,852,000,000 $-53.8%
Earnings release date:24 Jan. 24
Net income (shareholders):
2,168,000,000 $+51.0%
Free cash flow:
1,844,000,000 $+55.2%
Total:
4,012,000,000 $+52.9%
Earnings release date:18 Oct. 23
Net income (shareholders):
1,436,000,000 $+2419.3%
Free cash flow:
1,188,000,000 $+158.8%
Total:
2,624,000,000 $+408.5%
Earnings release date:20 Jul. 23
Net income (shareholders):
57,000,000 $-95.7%
Free cash flow:
459,000,000 $-39.8%
Total:
516,000,000 $-75.2%
Earnings release date:19 Apr. 23
Net income (shareholders):
1,318,000,000 $+27.6%
Free cash flow:
763,000,000 $+155.3%
Total:
2,081,000,000 $+56.2%
Earnings release date:25 Jan. 23
Net income (shareholders):
1,033,000,000 $-28.0%
Free cash flow:
298,900,000 $-91.3%
Total:
1,331,900,000 $-72.6%
Earnings release date:19 Oct. 22
Net income (shareholders):
1,435,000,000 $-28.9%
Free cash flow:
3,420,000,000 $+40.9%
Total:
4,855,000,000 $+9.2%
Earnings release date:20 Jul. 22
Net income (shareholders):
2,018,000,000 $
Free cash flow:
2,428,000,000 $
Total:
4,446,000,000 $

Profit margin in %

Profit margin in %Table view

Earnings release date
Profit margin (shareholders)
Profit margin (free cash flow)
Earnings release date:16 Jul. 26
Profit margin (shareholders):
7.37 %-2.3 pp
Profit margin (free cash flow):
16.55 %+8.3 pp
Earnings release date:16 Apr. 26
Profit margin (shareholders):
9.65 %-9.6 pp
Profit margin (free cash flow):
8.2 %-10.8 pp
Earnings release date:22 Jan. 26
Profit margin (shareholders):
19.25 %+4.8 pp
Profit margin (free cash flow):
19.04 %-22.9 pp
Earnings release date:15 Oct. 25
Profit margin (shareholders):
14.46 %+10.4 pp
Profit margin (free cash flow):
41.95 %+27.5 pp
Earnings release date:17 Jul. 25
Profit margin (shareholders):
4.07 %-8.7 pp
Profit margin (free cash flow):
14.47 %+5.5 pp
Earnings release date:16 Apr. 25
Profit margin (shareholders):
12.79 %-71.3 pp
Profit margin (free cash flow):
9.01 %-17.9 pp
Earnings release date:22 Jan. 25
Profit margin (shareholders):
84.1 %+68.6 pp
Profit margin (free cash flow):
26.95 %-5.7 pp
Earnings release date:16 Oct. 24
Profit margin (shareholders):
15.48 %+2.9 pp
Profit margin (free cash flow):
32.69 %+14.2 pp
Earnings release date:18 Jul. 24
Profit margin (shareholders):
12.55 %+0.3 pp
Profit margin (free cash flow):
18.46 %+12.2 pp
Earnings release date:17 Apr. 24
Profit margin (shareholders):
12.29 %-8.9 pp
Profit margin (free cash flow):
6.29 %-11.7 pp
Earnings release date:24 Jan. 24
Profit margin (shareholders):
21.17 %+7.0 pp
Profit margin (free cash flow):
18.01 %+6.3 pp
Earnings release date:18 Oct. 23
Profit margin (shareholders):
14.16 %+13.6 pp
Profit margin (free cash flow):
11.71 %+7.1 pp
Earnings release date:20 Jul. 23
Profit margin (shareholders):
0.57 %-13.0 pp
Profit margin (free cash flow):
4.6 %-3.2 pp
Earnings release date:19 Apr. 23
Profit margin (shareholders):
13.52 %+3.3 pp
Profit margin (free cash flow):
7.83 %+4.9 pp
Earnings release date:25 Jan. 23
Profit margin (shareholders):
10.24 %-3.5 pp
Profit margin (free cash flow):
2.96 %-29.9 pp
Earnings release date:19 Oct. 22
Profit margin (shareholders):
13.78 %-4.1 pp
Profit margin (free cash flow):
32.85 %+11.3 pp
Earnings release date:20 Jul. 22
Profit margin (shareholders):
17.93 %
Profit margin (free cash flow):
21.57 %

Revenue by segment

Revenue by segmentTable view

Earnings release date
Nutrition
Diagnostics
Established Pharmaceuticals
Medical Devices
Other
Total
Earnings release date:16 Jul. 26
Nutrition:
2,144,000,000 $+6.3%
Diagnostics:
3,092,000,000 $+41.8%
Established Pharmaceuticals:
1,499,000,000 $+5.1%
Medical Devices:
5,853,000,000 $+5.7%
Other:
5,000,000 $+150.0%
Total:
12,593,000,000 $+12.8%
Earnings release date:16 Apr. 26
Nutrition:
2,017,000,000 $+4.0%
Diagnostics:
2,180,000,000 $-11.3%
Established Pharmaceuticals:
1,426,000,000 $+3.2%
Medical Devices:
5,539,000,000 $-2.4%
Other:
2,000,000 $-60.0%
Total:
11,164,000,000 $-2.6%
Earnings release date:22 Jan. 26
Nutrition:
1,940,000,000 $-9.9%
Diagnostics:
2,457,000,000 $+9.1%
Established Pharmaceuticals:
1,382,000,000 $-8.5%
Medical Devices:
5,675,000,000 $+4.2%
Other:
5,000,000 $+25.0%
Total:
11,459,000,000 $+0.8%
Earnings release date:15 Oct. 25
Nutrition:
2,153,000,000 $-2.7%
Diagnostics:
2,253,000,000 $+3.7%
Established Pharmaceuticals:
1,511,000,000 $+9.3%
Medical Devices:
5,448,000,000 $+1.5%
Other:
4,000,000 $-20.0%
Total:
11,369,000,000 $+2.0%
Earnings release date:17 Jul. 25
Nutrition:
2,212,000,000 $+3.1%
Diagnostics:
2,173,000,000 $+5.8%
Established Pharmaceuticals:
1,383,000,000 $+9.8%
Medical Devices:
5,369,000,000 $+9.7%
Other:
5,000,000 $+66.7%
Total:
11,142,000,000 $+7.6%
Earnings release date:16 Apr. 25
Nutrition:
2,146,000,000 $+0.8%
Diagnostics:
2,054,000,000 $-18.5%
Established Pharmaceuticals:
1,260,000,000 $-0.6%
Medical Devices:
4,895,000,000 $-3.1%
Other:
3,000,000 $-40.0%
Total:
10,358,000,000 $-5.6%
Earnings release date:22 Jan. 25
Nutrition:
2,129,000,000 $+3.0%
Diagnostics:
2,520,000,000 $+4.5%
Established Pharmaceuticals:
1,268,000,000 $-9.8%
Medical Devices:
5,052,000,000 $+6.4%
Other:
5,000,000 $+25.0%
Total:
10,974,000,000 $+3.2%
Earnings release date:16 Oct. 24
Nutrition:
2,066,000,000 $-3.9%
Diagnostics:
2,412,000,000 $+9.9%
Established Pharmaceuticals:
1,406,000,000 $+8.7%
Medical Devices:
4,747,000,000 $+0.3%
Other:
4,000,000 $+0.0%
Total:
10,635,000,000 $+2.5%
Earnings release date:18 Jul. 24
Nutrition:
2,150,000,000 $+4.0%
Diagnostics:
2,195,000,000 $-0.9%
Established Pharmaceuticals:
1,294,000,000 $+5.5%
Medical Devices:
4,734,000,000 $+6.3%
Other:
4,000,000 $+33.3%
Total:
10,377,000,000 $+4.1%
Earnings release date:17 Apr. 24
Nutrition:
2,068,000,000 $+1.5%
Diagnostics:
2,214,000,000 $-12.6%
Established Pharmaceuticals:
1,226,000,000 $+0.3%
Medical Devices:
4,453,000,000 $+0.2%
Other:
3,000,000 $-25.0%
Total:
9,964,000,000 $-2.7%
Earnings release date:24 Jan. 24
Nutrition:
2,038,000,000 $-1.7%
Diagnostics:
2,534,000,000 $+3.5%
Established Pharmaceuticals:
1,222,000,000 $-10.7%
Medical Devices:
4,443,000,000 $+4.6%
Other:
4,000,000 $+0.0%
Total:
10,241,000,000 $+1.0%
Earnings release date:18 Oct. 23
Nutrition:
2,073,000,000 $-0.1%
Diagnostics:
2,449,000,000 $+5.7%
Established Pharmaceuticals:
1,368,000,000 $+6.3%
Medical Devices:
4,249,000,000 $-1.1%
Other:
4,000,000 $+33.3%
Total:
10,143,000,000 $+1.7%
Earnings release date:20 Jul. 23
Nutrition:
2,076,000,000 $+5.5%
Diagnostics:
2,317,000,000 $-13.8%
Established Pharmaceuticals:
1,287,000,000 $+8.2%
Medical Devices:
4,295,000,000 $+10.1%
Other:
3,000,000 $+0.0%
Total:
9,978,000,000 $+2.4%
Earnings release date:19 Apr. 23
Nutrition:
1,967,000,000 $+8.3%
Diagnostics:
2,688,000,000 $-18.7%
Established Pharmaceuticals:
1,189,000,000 $-2.2%
Medical Devices:
3,900,000,000 $+4.0%
Other:
3,000,000 $+0.0%
Total:
9,747,000,000 $-3.4%
Earnings release date:25 Jan. 23
Nutrition:
1,817,000,000 $+1.2%
Diagnostics:
3,305,000,000 $-10.0%
Established Pharmaceuticals:
1,216,000,000 $-8.3%
Medical Devices:
3,750,000,000 $+3.7%
Other:
3,000,000 $+0.0%
Total:
10,091,000,000 $-3.1%
Earnings release date:19 Oct. 22
Nutrition:
1,795,000,000 $-8.1%
Diagnostics:
3,671,000,000 $-15.1%
Established Pharmaceuticals:
1,326,000,000 $+8.4%
Medical Devices:
3,615,000,000 $-3.8%
Other:
3,000,000 $+50.0%
Total:
10,410,000,000 $-7.5%
Earnings release date:20 Jul. 22
Nutrition:
1,953,000,000 $
Diagnostics:
4,322,000,000 $
Established Pharmaceuticals:
1,223,000,000 $
Medical Devices:
3,757,000,000 $
Other:
2,000,000 $
Total:
11,257,000,000 $

Revenue by geographic location

Revenue by geographic locationTable view

Earnings release date
United States
International
Total
Earnings release date:16 Jul. 26
United States:
5,216,000,000 $+22.0%
International:
7,377,000,000 $+7.1%
Total:
12,593,000,000 $+12.8%
Earnings release date:16 Apr. 26
United States:
4,274,000,000 $-2.5%
International:
6,890,000,000 $-2.6%
Total:
11,164,000,000 $-2.6%
Earnings release date:22 Jan. 26
United States:
4,383,000,000 $+2.0%
International:
7,076,000,000 $+0.1%
Total:
11,459,000,000 $+0.8%
Earnings release date:15 Oct. 25
United States:
4,299,000,000 $+0.5%
International:
7,070,000,000 $+3.0%
Total:
11,369,000,000 $+2.0%
Earnings release date:17 Jul. 25
United States:
4,276,000,000 $+2.6%
International:
6,866,000,000 $+10.9%
Total:
11,142,000,000 $+7.6%
Earnings release date:16 Apr. 25
United States:
4,168,000,000 $-4.0%
International:
6,190,000,000 $-6.7%
Total:
10,358,000,000 $-5.6%
Earnings release date:22 Jan. 25
United States:
4,341,000,000 $+3.3%
International:
6,633,000,000 $+3.1%
Total:
10,974,000,000 $+3.2%
Earnings release date:16 Oct. 24
United States:
4,202,000,000 $+6.8%
International:
6,433,000,000 $-0.2%
Total:
10,635,000,000 $+2.5%
Earnings release date:18 Jul. 24
United States:
3,934,000,000 $+2.3%
International:
6,443,000,000 $+5.3%
Total:
10,377,000,000 $+4.1%
Earnings release date:17 Apr. 24
United States:
3,846,000,000 $-2.6%
International:
6,118,000,000 $-2.8%
Total:
9,964,000,000 $-2.7%
Earnings release date:24 Jan. 24
United States:
3,949,000,000 $+3.5%
International:
6,292,000,000 $-0.5%
Total:
10,241,000,000 $+1.0%
Earnings release date:18 Oct. 23
United States:
3,817,000,000 $+1.6%
International:
6,326,000,000 $+1.7%
Total:
10,143,000,000 $+1.7%
Earnings release date:20 Jul. 23
United States:
3,758,000,000 $-4.3%
International:
6,220,000,000 $+6.9%
Total:
9,978,000,000 $+2.4%
Earnings release date:19 Apr. 23
United States:
3,928,000,000 $-6.9%
International:
5,819,000,000 $-0.9%
Total:
9,747,000,000 $-3.4%
Earnings release date:25 Jan. 23
United States:
4,219,000,000 $+3.1%
International:
5,872,000,000 $-7.0%
Total:
10,091,000,000 $-3.1%
Earnings release date:19 Oct. 22
United States:
4,094,000,000 $-16.3%
International:
6,316,000,000 $-0.8%
Total:
10,410,000,000 $-7.5%
Earnings release date:20 Jul. 22
United States:
4,892,000,000 $
International:
6,365,000,000 $
Total:
11,257,000,000 $

Operating expenses

Operating expensesTable view

Earnings release date
Cost of products sold
Amortization of intangible assets
Research and development
Selling, general and administrative
Total
Earnings release date:16 Jul. 26
Cost of products sold:
5,325,000,000 $+8.9%
Amortization of intangible assets:
658,000,000 $+55.9%
Research and development:
892,000,000 $+16.3%
Selling, general and administrative:
4,025,000,000 $+7.6%
Total:
10,900,000,000 $+11.0%
Earnings release date:16 Apr. 26
Cost of products sold:
4,890,000,000 $-0.7%
Amortization of intangible assets:
422,000,000 $+0.0%
Research and development:
767,000,000 $+4.4%
Selling, general and administrative:
3,740,000,000 $+19.5%
Total:
9,819,000,000 $+6.6%
Earnings release date:22 Jan. 26
Cost of products sold:
4,922,000,000 $-3.0%
Amortization of intangible assets:
422,000,000 $+0.5%
Research and development:
735,000,000 $-4.0%
Selling, general and administrative:
3,129,000,000 $+2.6%
Total:
9,208,000,000 $-1.1%
Earnings release date:15 Oct. 25
Cost of products sold:
5,075,000,000 $+4.6%
Amortization of intangible assets:
420,000,000 $+0.0%
Research and development:
766,000,000 $+5.7%
Selling, general and administrative:
3,051,000,000 $-1.3%
Total:
9,312,000,000 $+2.4%
Earnings release date:17 Jul. 25
Cost of products sold:
4,854,000,000 $+8.6%
Amortization of intangible assets:
420,000,000 $+0.0%
Research and development:
725,000,000 $+1.3%
Selling, general and administrative:
3,091,000,000 $+1.0%
Total:
9,090,000,000 $+4.9%
Earnings release date:16 Apr. 25
Cost of products sold:
4,468,000,000 $-9.6%
Amortization of intangible assets:
420,000,000 $-9.7%
Research and development:
716,000,000 $-4.4%
Selling, general and administrative:
3,061,000,000 $+5.3%
Total:
8,665,000,000 $-4.4%
Earnings release date:22 Jan. 25
Cost of products sold:
4,942,000,000 $+5.2%
Amortization of intangible assets:
465,000,000 $-1.1%
Research and development:
749,000,000 $+5.0%
Selling, general and administrative:
2,907,000,000 $+0.4%
Total:
9,063,000,000 $+3.3%
Earnings release date:16 Oct. 24
Cost of products sold:
4,698,000,000 $+2.1%
Amortization of intangible assets:
470,000,000 $-0.2%
Research and development:
713,000,000 $+2.1%
Selling, general and administrative:
2,895,000,000 $-1.4%
Total:
8,776,000,000 $+0.8%
Earnings release date:18 Jul. 24
Cost of products sold:
4,603,000,000 $+3.1%
Amortization of intangible assets:
471,000,000 $-0.2%
Research and development:
698,000,000 $+2.0%
Selling, general and administrative:
2,936,000,000 $-0.8%
Total:
8,708,000,000 $+1.5%
Earnings release date:17 Apr. 24
Cost of products sold:
4,463,000,000 $-2.0%
Amortization of intangible assets:
472,000,000 $-1.9%
Research and development:
684,000,000 $-2.3%
Selling, general and administrative:
2,959,000,000 $+8.6%
Total:
8,578,000,000 $+1.4%
Earnings release date:24 Jan. 24
Cost of products sold:
4,556,000,000 $-1.1%
Amortization of intangible assets:
481,000,000 $-3.0%
Research and development:
700,000,000 $+4.2%
Selling, general and administrative:
2,724,000,000 $+0.0%
Total:
8,461,000,000 $-0.4%
Earnings release date:18 Oct. 23
Cost of products sold:
4,605,000,000 $+2.7%
Amortization of intangible assets:
496,000,000 $-0.4%
Research and development:
672,000,000 $-6.0%
Selling, general and administrative:
2,723,000,000 $-0.6%
Total:
8,496,000,000 $+0.7%
Earnings release date:20 Jul. 23
Cost of products sold:
4,483,000,000 $+3.5%
Amortization of intangible assets:
498,000,000 $+1.4%
Research and development:
715,000,000 $+9.3%
Selling, general and administrative:
2,740,000,000 $-0.8%
Total:
8,436,000,000 $+2.4%
Earnings release date:19 Apr. 23
Cost of products sold:
4,331,000,000 $-5.7%
Amortization of intangible assets:
491,000,000 $-1.0%
Research and development:
654,000,000 $-9.8%
Selling, general and administrative:
2,762,000,000 $-7.1%
Total:
8,238,000,000 $-6.2%
Earnings release date:25 Jan. 23
Cost of products sold:
4,593,000,000 $-0.8%
Amortization of intangible assets:
496,000,000 $-0.4%
Research and development:
725,000,000 $-7.3%
Selling, general and administrative:
2,973,000,000 $+8.9%
Total:
8,787,000,000 $+1.7%
Earnings release date:19 Oct. 22
Cost of products sold:
4,629,000,000 $-6.2%
Amortization of intangible assets:
498,000,000 $-1.8%
Research and development:
782,000,000 $+14.3%
Selling, general and administrative:
2,731,000,000 $-0.9%
Total:
8,640,000,000 $-2.7%
Earnings release date:20 Jul. 22
Cost of products sold:
4,933,000,000 $
Amortization of intangible assets:
507,000,000 $
Research and development:
684,000,000 $
Selling, general and administrative:
2,757,000,000 $
Total:
8,881,000,000 $

Capital expenditure

Capital expenditureTable view

Earnings release date
Capital expenditure
Earnings release date:16 Jul. 26
Capital expenditure:
497,000,000 $+24.6%
Earnings release date:16 Apr. 26
Capital expenditure:
399,000,000 $-39.4%
Earnings release date:22 Jan. 26
Capital expenditure:
658,000,000 $-55.6%
Earnings release date:15 Oct. 25
Capital expenditure:
1,482,000,000 $+195.2%
Earnings release date:17 Jul. 25
Capital expenditure:
502,000,000 $+3.7%
Earnings release date:16 Apr. 25
Capital expenditure:
484,000,000 $-14.9%
Earnings release date:22 Jan. 25
Capital expenditure:
569,000,000 $+1.4%
Earnings release date:16 Oct. 24
Capital expenditure:
561,000,000 $+5.3%
Earnings release date:18 Jul. 24
Capital expenditure:
533,000,000 $+33.9%
Earnings release date:17 Apr. 24
Capital expenditure:
398,000,000 $-31.0%
Earnings release date:24 Jan. 24
Capital expenditure:
577,000,000 $-11.6%
Earnings release date:18 Oct. 23
Capital expenditure:
653,000,000 $+34.1%
Earnings release date:20 Jul. 23
Capital expenditure:
487,000,000 $+28.2%
Earnings release date:19 Apr. 23
Capital expenditure:
380,000,000 $-14.2%
Earnings release date:25 Jan. 23
Capital expenditure:
443,000,000 $+7.3%
Earnings release date:19 Oct. 22
Capital expenditure:
413,000,000 $+6.2%
Earnings release date:20 Jul. 22
Capital expenditure:
389,000,000 $